Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK.
T Alexander Russell-SmithJames BrockbankCarla MamoloChristopher KnightPublished in: PharmacoEconomics - open (2021)
The ICERs for both populations met NICE's £20,000-£30,000 willingness-to-pay threshold for medicines and supported the current approval for GO.